Atezolizumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Atezolizumab and local guidelines before prescribing.
Immune checkpoint inhibitor
Mechanism
PD-L1 inhibitor.
Uses
Lung, urothelial, liver, breast cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related pneumonitis, hepatitis, colitis, endocrinopathies.
Interactions
Steroids reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
TFT, LFT, cortisol
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Immune toxicity pathway as for other checkpoint inhibitors.
More from the textbook: uses, cautions and other points
- Mechanism: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) release the brakes on the immune system. As well as attacking the cancer, they can cause immune-related adverse events in almost any organ - at any time, even months after stopping.
Respiratory: Lung Cancer - Atezolizumab plus bevacizumab , or durvalumab plus tremelimumab (first line).
Gastroenterology: Cirrhosis and Transplantation - Atezolizumab + bevacizumab | First-line advanced HCC (Child–Pugh A); check varices before bevacizumab.
Gastroenterology: Cirrhosis and Transplantation - Platinum-etoposide chemotherapy plus immunotherapy ( atezolizumab or durvalumab), then maintenance immunotherapy.
Respiratory: Lung Cancer - PD-L1 inhibitors - atezolizumab, durvalumab.
Oncology: Principles - Anti-PD-L1 - atezolizumab, durvalumab, avelumab.
Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology
Where it is discussed in the book
- Respiratory: Lung Cancer (2 mentions)
- Gastroenterology: Cirrhosis and Transplantation (2 mentions)
- Oncology: Principles (1 mention)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (1 mention)
- Integrated respiratory chapter (2 mentions)